APVO Aptevo Therapeutics Inc.
1.840USD+2.51%Mkt Cap: 3.33M $P/E: 0.031d ago
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company…
Industry Peers
Biotechnology$128.08BUSDP/E 29.4
$78.44BUSD
$76.40BUSDP/E 18.4
$57.03BUSDP/E 37.3
$58.08BUSDP/E 35.4
$42.24BUSDP/E 18.0
$43.05BUSD
$41.41BUSDP/E 65.1
$32.80BUSDP/E 30.2
$30.03BUSDP/E 37.8
$25.10BUSD
$23.93BUSD
$22.99BUSDP/E 14.5
$22.27BUSDP/E 30.7
$22.54BUSDP/E 28.9
$22.22BUSD
$15.03BUSDP/E 17.5
$15.01BUSDP/E 15.8
$14.48BUSDP/E 18.4
$14.32BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
 Aptevo Reports 93% Clinical Benefit Rate for Mipletamig Triplet in TP53-Mutated AML The early RAINIER data showed a 79% CR/CRi rate in evaluable frontline TP53-mutated AML patients, comparing favorably with a published 41% composite remission benchmark for venetoclax plus azacitidine. Key Investor TakeawaysAptevo Therapeutics Inc. | ||